Stock DNA
Pharmaceuticals & Biotechnology
USD 203 Million (Micro Cap)
14.00
NA
162.65%
-0.70
10.68%
1.73
Total Returns (Price + Dividend) 
Utah Medical Products, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is Utah Medical Products, Inc. technically bullish or bearish?
As of 11 September 2025, the technical trend for Utah Medical Products, Inc. has changed from sideways to bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, indicating positive momentum. Bollinger Bands are bullish for both weekly and monthly periods, reinforcing the bullish stance. Daily moving averages also confirm a bullish trend. The KST is bullish weekly and mildly bullish monthly, while the Dow Theory shows a mildly bullish stance on the monthly timeframe. In terms of performance, the stock has returned 11.01% over the past month, significantly outperforming the S&P 500's 2.33% return, but it has underperformed over longer periods, such as the 1-year return of -5.62% compared to the S&P 500's 17.14%. Overall, the current technical stance is bullish, with moderate strength indicated by multiple bullish signals across different timeframes....
Read MoreIs Utah Medical Products, Inc. overvalued or undervalued?
As of 7 July 2025, the valuation grade for Utah Medical Products, Inc. has moved from expensive to attractive, indicating a shift in perception regarding its value. The company appears undervalued, supported by a P/E ratio of 14, an EV to EBIT of 7.70, and a Price to Book Value of 1.56. In comparison, its peer CareDx, Inc. has a significantly higher P/E ratio of approximately 27.91, while Tactile Systems Technology, Inc. shows an EV to EBITDA of 9.59, further illustrating Utah Medical's relative valuation appeal. Despite the attractive valuation, Utah Medical's recent stock performance has lagged behind the S&P 500, with a 1-year return of -5.62% compared to the S&P 500's 17.14%. This underperformance over the longer term, particularly a 3-year return of -26.66% versus the S&P 500's 70.41%, may raise concerns among investors, but the current valuation metrics suggest that the stock could be a compelling op...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 50 Schemes (37.83%)
Held by 34 Foreign Institutions (3.66%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 3.09% vs 5.43% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 0.00% vs 3.45% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -18.53% vs -4.02% in Dec 2023
YoY Growth in year ended Dec 2024 is -16.27% vs 0.61% in Dec 2023






